Telomir Pharmaceuticals reported that its lead small‑molecule candidate, Telomir‑1 (also referred to as Telomir‑Zn), produced broad tumor cell mortality across a panel of triple‑negative breast cancer (TNBC) cell lines in vitro. Near‑complete cell death was observed in the MDA‑MB‑468 model, while significant partial reductions were seen in HCC70 and MDA‑MB‑231. Iron‑rescue experiments attenuated the effect, confirming an iron‑dependent mechanism rather than nonspecific cytotoxicity.
The findings expand Telomir‑1’s potential indications beyond its earlier focus on prostate cancer and age‑related diseases, indicating a potentially wide therapeutic window for the compound. The company has completed IND‑enabling GLP toxicology and safety pharmacology studies in rats and dogs, reporting no treatment‑related adverse toxicity, and plans to file an Investigational New Drug application in the first quarter of 2026 with first‑in‑human dosing slated for the first half of 2026.
"Triple‑negative breast cancer remains an area of significant unmet need, particularly in metastatic settings where long‑term survival remains limited," said Erez Aminov, Chief Executive Officer of Telomir Pharmaceuticals. "Demonstrating iron‑dependent tumor cell mortality across biologically distinct subtypes provides mechanistic validation as we advance toward clinical development." Dr. Itzchak Angel, Chief Scientific Advisor, added, "TNBC tumors are characterized by dysregulated metal metabolism and oxidative stress. The ability to modulate intracellular iron and observe subtype‑spanning tumor cell mortality supports a rational biological framework as the program progresses toward IND."
The data position Telomir as a potential therapy for an aggressive cancer type with limited options, reinforcing the company’s focus on epigenetic and metabolic drivers of disease. This milestone is a key operational step that underpins the company’s strategy to move Telomir‑1 forward in the regulatory pipeline and broaden its therapeutic portfolio.
The announcement represents a significant step forward for Telomir’s clinical development plan, strengthening the scientific profile of Telomir‑1 and setting the stage for regulatory submission and human trials.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.